Abstract: The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.
Type:
Grant
Filed:
September 3, 2003
Date of Patent:
April 18, 2006
Assignee:
SmithKline Beecham Biologicals (S.A.)
Inventors:
Patricia Marie Momin, Nathalie Marie-Josephe Garcon
Abstract: The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The invention provides Neisseria meningitidis BASB030 polypeptides and polynucleotides encoding BASB030 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are antibodies, diagnostic, prophylactic and therapeutic uses thereof.
Type:
Grant
Filed:
May 26, 1999
Date of Patent:
February 7, 2006
Assignee:
Smithkline Beecham Biologicals S.A.
Inventors:
Jean-Louis Ruelle, Johannes Petrus Maria Tommassen
Abstract: A process for the production of inactivated Hepatitis A virus substantially free of host cell contamination is described, the process comprising: a) culturing Hepatitis A virus and harvesting a Hepatitis A preparation; b) treating said Hepatitis A preparation with a protease; and thereafter c) separating intact virus from protease digested material; d) inactivating said virus. Also described are vaccines comprising the inactivated Hepatitis A virus, preferably in combination with strong adjuvants.
Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.
Abstract: Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.
Type:
Grant
Filed:
August 23, 2002
Date of Patent:
August 23, 2005
Assignee:
SmithKline Beecham Biologicals S.A.
Inventors:
Jean Stephenne, Martine Anne Cecile Wettendorff
Abstract: A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and anitbody titres than know commercial vaccines.
Type:
Grant
Filed:
November 3, 2003
Date of Patent:
May 31, 2005
Assignee:
SmithKline Beecham Biologicals, s.a.
Inventors:
Nigel Maurice Harford, Brigitte Desiree Alberte Colau, Jean Didelez
Abstract: A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.
Type:
Grant
Filed:
June 19, 2003
Date of Patent:
May 17, 2005
Assignee:
SmithKline Beecham Biologicals s.a.
Inventors:
Nathalie Marie-Josephe Claude Garcon-Johnson, Pierre Hauser, Clothilde Thiriart, Pierre Voet
Abstract: A novel adjuvant composition comprising a sterol (e.g., cholesterol, ?-sitosterol, stigmasterol, ergosterol, and ergocalciferol) and saponin fraction (e.g., QS21, also known as QA21) in the form of an immunostimulating complex, or ISCOM, is disclosed. QS21 is an immunologically active saponin fraction having adjuvant activity derived from the bark of Quillaja Saponaria Molina. Previous attempts in the prior art to prepare ISCOMs comprising QS21 were unsuccessful. Thus, the instant application discloses the first successful attempt to prepare ISCOMs comprising purified QS21. Small unilamelar liposomes containing cholesterol, in the absence of any detergent, were prepared, followed by the addition of an aqueous solution of QS21. The claimed compositions will prove useful in the preparation of highly immunogenic vaccine compositions.
Type:
Grant
Filed:
January 6, 2000
Date of Patent:
January 25, 2005
Assignee:
SmithKline Beecham Biologicals s.a.
Inventors:
Nathalie Marie-Josephe Claude Garcon, Martin Friede
Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The invention provides BASB040 polypeptides and polynucleotides from Neisseria meningitidis encoding BASB040 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The invention provides BASB029 polypeptides and polynucleotides encoding BASB029 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: Novel vaccine compositions are provided comprising a hepatitis B antigen formulated with aluminium phosphate. The vaccine compositions may additionally contain an inactivated hepatitis A virus, aluminium hydroxide and formol. The combined hepatitis A and B vaccine formulations can, if desired, be administered to human subjects in a 2 dose regimen. Suitable formulations are illustrated.
Type:
Application
Filed:
July 1, 2004
Publication date:
December 2, 2004
Applicant:
SmithKline Beecham Biologicals, s.a.
Inventors:
Claude Artois, Michael J. Clark, Stefan Gabriel Jozef Thoelen, Clothilde Thiriart
Abstract: This invention relates to a vaccine composition comprising: (a) one or more Streptococcus pneumoniae polysaccharides either conjugated to a protein or peptide, or non-conjugated; and (b) an RSV antigen in conjunction with an adjuvant which is a preferential stimulator of a Th1 type immune response. The combination vaccines provided by the invention are useful particularly for children and the elderly.
Type:
Application
Filed:
June 15, 2004
Publication date:
November 18, 2004
Applicant:
SmithKline Beecham Biologicals s.a.
Inventors:
Marguerite Deschamps, Craig Antony Joseph Laferriere
Abstract: A novel vaccine composition is provided which comprises: (a) a Salmonella typhi purified Vi polysaccharide; and (b) at least one other antigen wherein the vaccine components are stable and do not interfere with each other. The vaccine composition thus makes possible a single vaccination for protection against typhoid and other diseases such as hepatitis A, that travellers are prone to catch. Also described is a method of manufacturing Vi polysaccharide of S. typhi wherein the extraction and purification of the Vi polysaccharide is carried out in the absence of phenol.
Type:
Application
Filed:
May 12, 2004
Publication date:
October 28, 2004
Applicant:
SmithKline Beecham Biologicals, s.a.
Inventors:
Pascale Demil, Erik D'Hondt, Christian Van Hoecke
Abstract: The invention provides a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.
Type:
Application
Filed:
May 4, 2004
Publication date:
October 21, 2004
Applicant:
SmithKline Beecham Biologicals S.A.
Inventors:
Patrick Florent, Jean Stephenne, Christian Vandecasserie
Abstract: A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmitted diseases, for example an HSV glycoprotein D or an immunological fragment thereof, and an adjuvant, especially a TH-1 inducing adjuvant. The use of the vaccine components for the formulation of a vaccine composition for the prevention or treatment of sexually transmitted diseases in female subjects is also described.
Type:
Application
Filed:
January 20, 2004
Publication date:
August 5, 2004
Applicant:
SmithKline Beecham Biologicals s.a.
Inventors:
Moncef Mohamed Slaoui, Pierre G. Vandepapeliere
Abstract: The invention provides BASB041, 43, 44 and 48 polypeptides and polynucleotides encoding BASB041, 43, 44 and 48 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Type:
Application
Filed:
January 9, 2004
Publication date:
July 29, 2004
Applicant:
Smithkline Beecham Biologicals S.A.
Inventors:
Jean-Louis Ruelle, Vincent Georges Christian Louis Verlant